<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=129980757405201&amp;ev=PageView&amp;noscript=1">
    TRC | The Medication Learning Company - Update. Inform. Educate. Prescriber's Letter Pharmacist's Letter
NSAIDs and CV Risk

On-Demand Webinar
NSAIDs.jpg

Controversy continues over the safety of NSAIDs in patients at high cardiovascular risk. Although all NSAIDs have a “boxed” warning about increased CV risk, we typically avoid celecoxib (Celebrex, etc.) in patients at high CV risk and think of naproxen as a safer solution.

This month we are pleased to bring you a discussion about the PRECISION trial, the first big study that compares chronic NSAIDs in high-CV-risk patients. Our featured panelist is Dr. Steven Nissen, Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic. Dr. Nissen, our editors, and other frontline providers will give their perspective on:

  • How do NSAIDs compare in terms of CV safety?
  • What are some caveats to the PRECISION trial?
  • When might you consider an NSAID for a patient with CV disease or risk factors?
  • If an NSAID is necessary for a patient at high CV risk, which one should be used?

Complete the form to view this webinar now.